Nobuaki Tanaka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nobuaki Tanaka has a total of 312 co-authors. Here are the top co-authors by number of shared publications:
- Masato Okada
Cardiovascular Center, Sakurabashi Watanabe Advanced Healthcare Hospital Osaka Japan
33 shared publications - Yasushi Sakata
Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan
19 shared publications - Shungo Hikoso
Nara Medical University
18 shared publications - Yohei Sotomi
Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine
17 shared publications - Koji Tanaka
Cardiovascular Center, Sakurabashi Watanabe Advanced Healthcare Hospital, Osaka (N.T., M.O., K.T.).
15 shared publications - Koichi Inoue
Cardiovascular Division National Hospital Organization Osaka National Hospital Osaka Japan
13 shared publications
Latest Publications
- Open Access
- 22 September 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (10)
Strategy Selection and Outcomes of Tip-Detection in CTO-PCI
- 22 September 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (10)
Open AccessStrategy Selection and Outcomes of Tip-Detection in CTO-PCI
- Open Access
- 2 September 2026
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 6 (5)
Phenotypic clustering of atrial fibrillation patients using latent class analysis and its potential utility for ablation strategy: insights from the DIRECT-Extend and EARNEST-PVI studies
Aims: AF is a heterogeneous syndrome. We aimed to assess whether latent class analysis (LCA) can identify phenotypes that stratify prognosis and predict differential responses to catheter ablation strategies. Methods and results: We first developed an LCA-based phenotyping model using the DIRECT-Extend registry (N = 7512), a pooled AF cohort of patients receiving anticoagulation therapy. Patients with echocardiographic data (N = 2741) were classified into latent clusters based on 16 clinical, laboratory, and echocardiographic variables. This phenotypic classification was then applied to the randomized Effect of Extensive Ablation on Recurrence in Patients with Persistent AF Treated with Pulmonary Vein Isolation (EARNEST-PVI) trial to evaluate whether the effectiveness of ablation strategies—pulmonary vein isolation (PVI) alone vs. PVI plus extensive ablation (PVI-plus)—varied across phenotypes. In the DIRECT-Extend registry, three phenotypes were identified: Phenotype 1 (N = 1565; ‘low comorbidity’), Phenotype 2 (N = 981; ‘cardiomyopathy & chronic kidney disease’), and Phenotype 3 (N = 195; ‘inflammatory-enriched AF’). Over a median of 600 days, the primary endpoint—a composite of all-cause death, acute myocardial infarction, any stroke, and major bleeding differed across phenotypes (log-rank P < 0.001). In EARNEST-PVI, patients were stratified into Phenotype 1 (N = 328), Phenotype 2 (N = 139), and Phenotype 3 (N = 30) according to the classification model. AF recurrence was significantly lower in the PVI-plus group compared to the PVI-alone group in Phenotype 1 (log-rank P = 0.013), whereas there was no significant difference in Phenotypes 2 and 3. Conclusion: LCA identified distinct AF phenotypes associated with prognoses. These phenotypes may also provide insights into heterogeneity in response to ablation strategies. This phenotyping approach may support risk stratification and individualized AF management.
- 2 September 2026
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 6 (5)
Open AccessPhenotypic clustering of atrial fibrillation patients using latent class analysis and its potential utility for ablation strategy: insights from the DIRECT-Extend and EARNEST-PVI studies
Aims: AF is a heterogeneous syndrome. We aimed to assess whether latent class analysis (LCA) can identify phenotypes that stratify prognosis and predict differential responses to catheter ablation strategies. Methods and results: We first developed an LCA-based phenotyping model using the DIRECT-Extend registry (N = 7512), a pooled AF cohort of patients receiving anticoagulation therapy. Patients with echocardiographic data (N = 2741) were classified into latent clusters based on 16 clinical, laboratory, and echocardiographic variables. This phenotypic classification was then applied to the randomized Effect of Extensive Ablation on Recurrence in Patients with Persistent AF Treated with Pulmonary Vein Isolation (EARNEST-PVI) trial to evaluate whether the effectiveness of ablation strategies—pulmonary vein isolation (PVI) alone vs. PVI plus extensive ablation (PVI-plus)—varied across phenotypes. In the DIRECT-Extend registry, three phenotypes were identified: Phenotype 1 (N = 1565; ‘low comorbidity’), Phenotype 2 (N = 981; ‘cardiomyopathy & chronic kidney disease’), and Phenotype 3 (N = 195; ‘inflammatory-enriched AF’). Over a median of 600 days, the primary endpoint—a composite of all-cause death, acute myocardial infarction, any stroke, and major bleeding differed across phenotypes (log-rank P < 0.001). In EARNEST-PVI, patients were stratified into Phenotype 1 (N = 328), Phenotype 2 (N = 139), and Phenotype 3 (N = 30) according to the classification model. AF recurrence was significantly lower in the PVI-plus group compared to the PVI-alone group in Phenotype 1 (log-rank P = 0.013), whereas there was no significant difference in Phenotypes 2 and 3. Conclusion: LCA identified distinct AF phenotypes associated with prognoses. These phenotypes may also provide insights into heterogeneity in response to ablation strategies. This phenotyping approach may support risk stratification and individualized AF management.
- Open Access
The Risk Estimation by the PREVENT equations and Clinical Outcome in Patients with Heart Failure with Preserved Ejection Fraction
Background: The PREVENT (Predicting Risk of CVD EVENTs) equations estimate the risk of incident cardiovascular disease (CVD) in primary prevention patients. We hypothesized that risk factors incorporated in the equations may be relevant to prognosis in heart failure (HF) and investigated the association between estimated CVD risk and clinical outcomes in patients with preserved ejection fraction (HFpEF). Methods: We estimated the 10-year CVD risk using the PREVENT equations in 278 patients hospitalized for acutely decompensated HFpEF (median 75 years, 51.4% male). We divided them into four groups according to the quartiles of estimated CVD risk and followed them to observe major adverse cardiovascular events (MACE), a composite of all-cause death, HF hospitalization, and stroke. Results: MACE occurred in 125 patients (45.0%) over a median follow-up of 1,050 days. The estimated CVD risk classification was an independent predictor for MACE (p=0.02) in the multivariable Cox proportional hazard model. There was a difference in MACE-free survival across the four quartile groups (p<0.001 by log-rank test), and the lowest CVD risk group had significantly lower MACE incidence than other groups. The estimated CVD risk provided incremental prognostic value beyond N-terminal pro-B type natriuretic peptide (C-index: 0.626 vs, P=0.009). The predictive value of the estimated CVD risk for MACE at 1 year was comparable to that of the MAGGIC score (AUC 0.676 vs. 0.639, p=0.42). Conclusions: The 10-year CVD risk estimated by the PREVENT equations had a moderate predictive value for MACE in patients hospitalized for HFpEF.
Open AccessThe Risk Estimation by the PREVENT equations and Clinical Outcome in Patients with Heart Failure with Preserved Ejection Fraction
Background: The PREVENT (Predicting Risk of CVD EVENTs) equations estimate the risk of incident cardiovascular disease (CVD) in primary prevention patients. We hypothesized that risk factors incorporated in the equations may be relevant to prognosis in heart failure (HF) and investigated the association between estimated CVD risk and clinical outcomes in patients with preserved ejection fraction (HFpEF). Methods: We estimated the 10-year CVD risk using the PREVENT equations in 278 patients hospitalized for acutely decompensated HFpEF (median 75 years, 51.4% male). We divided them into four groups according to the quartiles of estimated CVD risk and followed them to observe major adverse cardiovascular events (MACE), a composite of all-cause death, HF hospitalization, and stroke. Results: MACE occurred in 125 patients (45.0%) over a median follow-up of 1,050 days. The estimated CVD risk classification was an independent predictor for MACE (p=0.02) in the multivariable Cox proportional hazard model. There was a difference in MACE-free survival across the four quartile groups (p<0.001 by log-rank test), and the lowest CVD risk group had significantly lower MACE incidence than other groups. The estimated CVD risk provided incremental prognostic value beyond N-terminal pro-B type natriuretic peptide (C-index: 0.626 vs, P=0.009). The predictive value of the estimated CVD risk for MACE at 1 year was comparable to that of the MAGGIC score (AUC 0.676 vs. 0.639, p=0.42). Conclusions: The 10-year CVD risk estimated by the PREVENT equations had a moderate predictive value for MACE in patients hospitalized for HFpEF.
- Open Access
- 16 June 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (12) , e047450
Impact of Diabetes on the Efficacy of Low‐Voltage Area Ablation for Persistent Atrial Fibrillation: A Subanalysis of the SUPPRESS‐AF Trial
Background: The potential value of low‐voltage area (LVA) ablation for persistent atrial fibrillation (AF) has been suggested. However, its efficacy determinants remain unclear. We investigated the impact of diabetes on the outcomes of LVA ablation in patients with persistent AF. Methods: This post hoc subanalysis of the multicenter randomized controlled trial SUPPRESS‐AF (Efficacy and Safety of Low‐Voltage‐Guided Ablation for Recurrence Prevention Compared With Pulmonary Vein Isolation Alone in Patients With Persistent Atrial Fibrillation) included patients with persistent AF undergoing initial ablation. Following pulmonary vein isolation (PVI), patients with LVAs were randomized to PVI+LVA‐ablation or PVI alone. We compared recurrence‐free survival between patients with and without diabetes. The primary end point was freedom from AF/atrial tachycardia recurrence. Results: Of 1347 patients with persistent AF, 343 (25.5%) had left atrial LVAs. The nondiabetic group comprised 264 patients (136 and 128 in the PVI‐alone and PVI+LVA‐ablation arms, respectively), and the diabetic group comprised 77 patients (35 and 42 in each arm, respectively). No significant difference was observed in LVA extent between the groups. Overall recurrence rates were also similar (44% versus 42%; P =0.658). In the nondiabetic group, the PVI+LVA‐ablation arm showed significantly lower recurrence rates compared with the PVI‐alone arm (35% versus 49%; P =0.018). Conversely, patients with diabetes exhibited higher recurrence rates in the PVI+LVA‐ablation arm compared with those in the PVI‐alone arm (48% versus 40%; P =0.290). A significant interaction was observed between diabetes status and LVA ablation efficacy ( P for interaction=0.041). Conclusions: In this exploratory post hoc analysis, LVA ablation may benefit patients without diabetes, whereas no clear benefit, and a possible signal of futility, was observed in patients with diabetes.
- 16 June 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (12) , e047450
Open AccessImpact of Diabetes on the Efficacy of Low‐Voltage Area Ablation for Persistent Atrial Fibrillation: A Subanalysis of the SUPPRESS‐AF Trial
Background: The potential value of low‐voltage area (LVA) ablation for persistent atrial fibrillation (AF) has been suggested. However, its efficacy determinants remain unclear. We investigated the impact of diabetes on the outcomes of LVA ablation in patients with persistent AF. Methods: This post hoc subanalysis of the multicenter randomized controlled trial SUPPRESS‐AF (Efficacy and Safety of Low‐Voltage‐Guided Ablation for Recurrence Prevention Compared With Pulmonary Vein Isolation Alone in Patients With Persistent Atrial Fibrillation) included patients with persistent AF undergoing initial ablation. Following pulmonary vein isolation (PVI), patients with LVAs were randomized to PVI+LVA‐ablation or PVI alone. We compared recurrence‐free survival between patients with and without diabetes. The primary end point was freedom from AF/atrial tachycardia recurrence. Results: Of 1347 patients with persistent AF, 343 (25.5%) had left atrial LVAs. The nondiabetic group comprised 264 patients (136 and 128 in the PVI‐alone and PVI+LVA‐ablation arms, respectively), and the diabetic group comprised 77 patients (35 and 42 in each arm, respectively). No significant difference was observed in LVA extent between the groups. Overall recurrence rates were also similar (44% versus 42%; P =0.658). In the nondiabetic group, the PVI+LVA‐ablation arm showed significantly lower recurrence rates compared with the PVI‐alone arm (35% versus 49%; P =0.018). Conversely, patients with diabetes exhibited higher recurrence rates in the PVI+LVA‐ablation arm compared with those in the PVI‐alone arm (48% versus 40%; P =0.290). A significant interaction was observed between diabetes status and LVA ablation efficacy ( P for interaction=0.041). Conclusions: In this exploratory post hoc analysis, LVA ablation may benefit patients without diabetes, whereas no clear benefit, and a possible signal of futility, was observed in patients with diabetes.
- Open Access
- 2 June 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (11) , e047814
Efficacy of Low‐Voltage Area Ablation Across Substrate Size in Persistent Atrial Fibrillation: A Post Hoc Analysis of the SUPPRESS‐AF Randomized Trial
Background: Larger low‐voltage areas (LVAs) in the left atrium are associated with increased arrhythmia recurrence after atrial fibrillation (AF) ablation. The benefit of adjunctive LVA ablation may therefore depend on substrate extent. This study examined the efficacy of LVA ablation across a spectrum of LVA sizes in persistent AF. Methods: The SUPPRESS‐AF (Efficacy and Safety of Left Atrial Low‐Voltage Area Guided Ablation for Recurrence Prevention Compared to Pulmonary Vein Isolation Alone in Patients With Persistent Atrial Fibrillation) trial screened 1364 patients undergoing initial ablation for persistent AF, of whom 342 with left atrial LVAs (≥5 cm 2 ) were randomized to pulmonary vein isolation with or without adjunctive LVA ablation. In the 341 analyzed patients, LVA size was categorized as small (2 , n=106), moderate (≥10 to 2 , n=127), or extensive (≥20 cm 2 , n=108). The primary end point was recurrence of AF or atrial tachycardia within 1 year without antiarrhythmic drugs. Treatment effects across LVA sizes were evaluated using a Cox model with restricted cubic splines. Results: AF/atrial tachycardia recurrence rates were similar between the pulmonary vein isolation+LVA ablation and pulmonary vein isolation‐alone groups in patients with small (38.5% versus 29.6%; P =0.28) and moderate LVA sizes (40.6% versus 53.5%; P =0.15). However, adjunctive LVA ablation significantly reduced recurrence in patients with extensive LVAs (34.7% versus 57.6%; P =0.029; interaction P =0.054), driven mainly by lower AF recurrence (18.4% versus 42.4%, P =0.008). Spline analysis indicated a greater treatment benefit with increasing LVA size, reaching significance around 20 cm 2 . Conclusions: The efficacy of adjunctive LVA ablation increased with substrate size, with a significant benefit observed in patients with extensive LVAs. These findings support a substrate size–guided ablation strategy to optimize rhythm outcomes in persistent AF. Registration: URL: https://www.umin.ac.jp/ctr ; Identifier: UMIN000035940.
- 2 June 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (11) , e047814
Open AccessEfficacy of Low‐Voltage Area Ablation Across Substrate Size in Persistent Atrial Fibrillation: A Post Hoc Analysis of the SUPPRESS‐AF Randomized Trial
Background: Larger low‐voltage areas (LVAs) in the left atrium are associated with increased arrhythmia recurrence after atrial fibrillation (AF) ablation. The benefit of adjunctive LVA ablation may therefore depend on substrate extent. This study examined the efficacy of LVA ablation across a spectrum of LVA sizes in persistent AF. Methods: The SUPPRESS‐AF (Efficacy and Safety of Left Atrial Low‐Voltage Area Guided Ablation for Recurrence Prevention Compared to Pulmonary Vein Isolation Alone in Patients With Persistent Atrial Fibrillation) trial screened 1364 patients undergoing initial ablation for persistent AF, of whom 342 with left atrial LVAs (≥5 cm 2 ) were randomized to pulmonary vein isolation with or without adjunctive LVA ablation. In the 341 analyzed patients, LVA size was categorized as small (2 , n=106), moderate (≥10 to 2 , n=127), or extensive (≥20 cm 2 , n=108). The primary end point was recurrence of AF or atrial tachycardia within 1 year without antiarrhythmic drugs. Treatment effects across LVA sizes were evaluated using a Cox model with restricted cubic splines. Results: AF/atrial tachycardia recurrence rates were similar between the pulmonary vein isolation+LVA ablation and pulmonary vein isolation‐alone groups in patients with small (38.5% versus 29.6%; P =0.28) and moderate LVA sizes (40.6% versus 53.5%; P =0.15). However, adjunctive LVA ablation significantly reduced recurrence in patients with extensive LVAs (34.7% versus 57.6%; P =0.029; interaction P =0.054), driven mainly by lower AF recurrence (18.4% versus 42.4%, P =0.008). Spline analysis indicated a greater treatment benefit with increasing LVA size, reaching significance around 20 cm 2 . Conclusions: The efficacy of adjunctive LVA ablation increased with substrate size, with a significant benefit observed in patients with extensive LVAs. These findings support a substrate size–guided ablation strategy to optimize rhythm outcomes in persistent AF. Registration: URL: https://www.umin.ac.jp/ctr ; Identifier: UMIN000035940.
- Open Access
- 21 May 2026
- Published by Elsevier in JACC: Asia
Triglyceride-Glucose Index and Clinical Outcome in Patients With Heart Failure With Preserved Ejection Fraction
- 21 May 2026
- Published by Elsevier in JACC: Asia
Open AccessTriglyceride-Glucose Index and Clinical Outcome in Patients With Heart Failure With Preserved Ejection Fraction
- Open Access
- 1 April 2026
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 19 (4) , e014408
Differential Impact of Low Voltage Area Radiofrequency Ablation on Recurrence of Atrial Fibrillation Versus Atrial Tachycardia in Patients With Persistent Atrial Fibrillation
- 1 April 2026
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 19 (4) , e014408
Open AccessDifferential Impact of Low Voltage Area Radiofrequency Ablation on Recurrence of Atrial Fibrillation Versus Atrial Tachycardia in Patients With Persistent Atrial Fibrillation
- Open Access
- 28 March 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (5) , 102704
Biophysical Scaling of Human Heart Rate
- 28 March 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (5) , 102704
Open AccessBiophysical Scaling of Human Heart Rate
- Open Access
- 17 February 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (4) , e044945
Clinical Implications of Left Atrial and Ventricular Reverse Remodeling After Atrial Fibrillation Ablation in Patients With Systolic Dysfunction
Background: Catheter ablation of atrial fibrillation (AF) is an effective treatment to achieve left atrial (LA) and left ventricular (LV) reverse remodeling in patients with systolic dysfunction. However, the relationship between LA and LV reverse remodeling (LARR and LVRR) and their clinical implications remains unclear. Methods: Among 5287 consecutive patients undergoing first‐time AF ablation, 620 with baseline LV ejection fraction P P <0.001), whereas LARR−/LVRR− (HR, 6.73 [95% CI, 3.48–13.0]) and LARR+/LVRR− (HR, 4.58 [95% CI, 1.86–11.3]) were associated with the composite end point. Conclusions: LARR and LVRR were moderately correlated after AF ablation in patients with systolic dysfunction. Their combined assessment delineated distinct postablation trajectories and may improve individual risk stratification.
- 17 February 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (4) , e044945
Open AccessClinical Implications of Left Atrial and Ventricular Reverse Remodeling After Atrial Fibrillation Ablation in Patients With Systolic Dysfunction
Background: Catheter ablation of atrial fibrillation (AF) is an effective treatment to achieve left atrial (LA) and left ventricular (LV) reverse remodeling in patients with systolic dysfunction. However, the relationship between LA and LV reverse remodeling (LARR and LVRR) and their clinical implications remains unclear. Methods: Among 5287 consecutive patients undergoing first‐time AF ablation, 620 with baseline LV ejection fraction P P <0.001), whereas LARR−/LVRR− (HR, 6.73 [95% CI, 3.48–13.0]) and LARR+/LVRR− (HR, 4.58 [95% CI, 1.86–11.3]) were associated with the composite end point. Conclusions: LARR and LVRR were moderately correlated after AF ablation in patients with systolic dysfunction. Their combined assessment delineated distinct postablation trajectories and may improve individual risk stratification.